23andme semaglutide As a medical school professor, I get asked why GLP-1 drugs work miracles for some and barely budge for others. A new Nature paper from gives part of the answer: your 23andMe jumps into GLP-1 weight

This intrauterine lethality has been related to increased apoptosis and cell death leading to malformation of embryonic structures and major defects in brain development (Imai et al., 2003)

Saldaa-Ruiz, S., et al

If approved, we believe pemvidutide could offer an important option for obesity patients, including those with risk factors for cardiovascular disease. However, tolerability issues remain, as the trial led to one participant experiencing vomiting, and 4.1% of the patients in the drug cohort discontinuing treatment in the first 16 weeks, when compared to 2.1% in the placebo group

doi: 10.1038/s41392-024-01931-z Rowlands J, Heng J, Newsholme P, Carlessi R